TWI862513B - 包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法 - Google Patents

包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法 Download PDF

Info

Publication number
TWI862513B
TWI862513B TW108133603A TW108133603A TWI862513B TW I862513 B TWI862513 B TW I862513B TW 108133603 A TW108133603 A TW 108133603A TW 108133603 A TW108133603 A TW 108133603A TW I862513 B TWI862513 B TW I862513B
Authority
TW
Taiwan
Prior art keywords
cells
insulin
group
positive
producing
Prior art date
Application number
TW108133603A
Other languages
English (en)
Chinese (zh)
Other versions
TW202026420A (zh
Inventor
伊藤亮
山添則子
日吉秀行
持田泰佑
上野光
佐久間健介
山浦順司
松本寛和
豊田太郎
小長谷周平
Original Assignee
日商千紙鶴治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商千紙鶴治療公司 filed Critical 日商千紙鶴治療公司
Publication of TW202026420A publication Critical patent/TW202026420A/zh
Application granted granted Critical
Publication of TWI862513B publication Critical patent/TWI862513B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW108133603A 2018-09-19 2019-09-18 包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法 TWI862513B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018175465 2018-09-19
JP2018-175465 2018-09-19

Publications (2)

Publication Number Publication Date
TW202026420A TW202026420A (zh) 2020-07-16
TWI862513B true TWI862513B (zh) 2024-11-21

Family

ID=69887298

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108133603A TWI862513B (zh) 2018-09-19 2019-09-18 包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法

Country Status (14)

Country Link
US (1) US20210353686A1 (cg-RX-API-DMAC7.html)
EP (1) EP3854869A4 (cg-RX-API-DMAC7.html)
JP (1) JP7295576B2 (cg-RX-API-DMAC7.html)
KR (1) KR102892433B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867787B (cg-RX-API-DMAC7.html)
AU (1) AU2019343003B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004815A2 (cg-RX-API-DMAC7.html)
CA (1) CA3113608A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003947A2 (cg-RX-API-DMAC7.html)
IL (1) IL281531B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003147A (cg-RX-API-DMAC7.html)
SG (1) SG11202102748WA (cg-RX-API-DMAC7.html)
TW (1) TWI862513B (cg-RX-API-DMAC7.html)
WO (1) WO2020059892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169351A1 (en) 2018-03-02 2019-09-06 Semma Therapeutics, Inc. Methods of enhancing stem cell differentiation into beta cells
CN112912490B (zh) * 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
JP7705448B2 (ja) 2020-07-31 2025-07-09 バーテックス ファーマシューティカルズ インコーポレイテッド 膵内分泌細胞の分化
CN116391028A (zh) * 2020-11-20 2023-07-04 千纸鹤治疗公司 促熟剂
TW202246489A (zh) * 2021-02-09 2022-12-01 日商千紙鶴治療公司 成熟化劑
JP2024542041A (ja) 2021-11-01 2024-11-13 バーテックス ファーマシューティカルズ インコーポレイテッド 幹細胞由来の膵臓島分化
IL315122A (en) * 2022-04-25 2024-10-01 Orizuru Therapeutics Inc Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
EP4596675A4 (en) 2022-09-26 2026-03-11 Univ Kyoto PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS
EP4753734A1 (en) * 2023-08-02 2026-06-10 Joslin Diabetes Center, Inc. Ribosomal remodeling in diabetes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005096873A1 (de) 2004-04-10 2005-10-20 Henkel Kommanditgesellschaft Auf Aktien Lockenwickler
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
NZ571427A (en) * 2006-03-02 2012-07-27 Viacyte Inc Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US7661738B2 (en) 2006-11-28 2010-02-16 Veritainer Corporation Radiation detection unit for mounting a radiation sensor to a container crane
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
JP2010528622A (ja) 2007-05-30 2010-08-26 ザ ジェネラル ホスピタル コーポレイション 体細胞から多能性細胞を生成する方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009012428A2 (en) 2007-07-18 2009-01-22 Lifescan, Inc. Differentiation of human embryonic stem cells
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US9540630B2 (en) 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
JP5875597B2 (ja) * 2010-12-08 2016-03-02 ヴィアサイト,インコーポレイテッド ヒト万能性幹細胞の成長を阻害する薬剤および方法
US20120270890A1 (en) * 2011-04-22 2012-10-25 Cheng-Ho Chung Methods of Pancreatic Beta Cell Regeneration
RU2705001C2 (ru) * 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
IL321825A (en) * 2013-02-06 2025-08-01 Viacyte Inc Cell compositions derived from dedifferentiated reprogrammed cells
WO2015002888A1 (en) * 2013-07-01 2015-01-08 Trustees Of Boston University Dissolvable hydrogel compositions for wound management and methods of use
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
CN107250349A (zh) * 2014-12-19 2017-10-13 詹森生物科技公司 多能干细胞的悬浮培养
HK1254740A1 (zh) * 2015-11-30 2019-07-26 Kadimastem Ltd. 分化和纯化胰腺内分泌细胞的方法
MA45329A (fr) * 2016-04-08 2019-02-13 Univ California Production de cellules bêta matures pleinement fonctionnelles à partir de progénitrices pancréatiques humaines
JP6863805B2 (ja) 2017-04-14 2021-04-21 グローリー株式会社 各台装置及び各台装置制御方法
AU2019261083B2 (en) * 2018-04-23 2025-01-23 Orizuru Therapeutics, Inc. Growth inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Felicia W Pagliuca et al., Generation of functional human pancreatic β cells in vitro. Cell. 159(2): doi: 10.1016/j.cell.2014.09.040. 2014 Oct 9; 428-439.
期刊 Yzumi Yamashita-Sugahara et al., An inhibitor of fibroblast growth factor receptor-1 (FGFR1) promotes late-stage terminal differentiation from NGN3+ pancreatic endocrine progenitors. Sci Rep. 6:35908. doi: 10.1038/srep35908. 2016 Oct 27: p1-14.

Also Published As

Publication number Publication date
AU2019343003A1 (en) 2021-05-13
CN112867787B (zh) 2024-11-22
IL281531B1 (en) 2024-11-01
KR20210060446A (ko) 2021-05-26
BR112021004815A2 (pt) 2021-06-01
IL281531A (en) 2021-05-31
TW202026420A (zh) 2020-07-16
MX2021003147A (es) 2021-05-14
WO2020059892A1 (ja) 2020-03-26
IL281531B2 (en) 2025-03-01
SG11202102748WA (en) 2021-04-29
CA3113608A1 (en) 2020-03-26
EP3854869A4 (en) 2022-09-07
CO2021003947A2 (es) 2021-04-19
CN112867787A (zh) 2021-05-28
JP7295576B2 (ja) 2023-06-21
US20210353686A1 (en) 2021-11-18
JPWO2020059892A1 (ja) 2021-08-30
KR102892433B1 (ko) 2025-11-27
EP3854869A1 (en) 2021-07-28
AU2019343003B2 (en) 2025-07-17

Similar Documents

Publication Publication Date Title
JP7295576B2 (ja) インスリン産生細胞
US20190390169A1 (en) Pancreatic progenitor cell production method
CN112313327B (zh) 增殖抑制剂
JP2025000878A (ja) 生体組織様構造体の製造方法
ES3026932T3 (en) Cell production method
RU2829220C2 (ru) Инсулинпродуцирующие клетки
RU2825665C2 (ru) Ингибитор роста
JPWO2017188082A1 (ja) 培地添加剤
WO2022172960A1 (ja) 成熟化剤